Skip to content

AlloSure Lung Assessment and Metagenomics Outcomes Study

Lung Transplant; Complications | Lung Transplant Infection | Lung Transplant Failure and Rejection

ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

1. Unilateral or Bilateral, deceased-donor, initial or re-transplant
2. ≤ 90 days post-transplant
3. Ability to understand and provide informed consent and adhere to laboratory surveillance schedule
4. Patients who have LungCare initiated within 30 days of signing the informed consent form

Exclusion Criteria:

1. Multi-organ transplants
2. Pregnancy
3. Active malignancy

Study Location

Toronto General Hospital
Toronto General Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Sharaniyaa Balachandran

Study Sponsored By
CareDx
Participants Required
More Information
Study ID: NCT05050955